This review focuses on recent advances in the use of immune-based therapy to treat patients with refractory and relapsing acquired thrombotic thrombocytopenic purpura.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by hemolytic anemia, consumptive thrombocytopenia, and ischemic injury [1] [2] [3] . The pathogenesis of TTP is attributed to the presence of unusually large von Willebrand factor (ul-vWF) multimers that lead to platelet clumping and subsequent microvascular thrombosis [4] . These ul-vWF multimers, primarily synthesized by vascular endothelial cells [5] , are normally cleaved into smaller protein units by a metalloprotease enzyme, the von Willebrand factor-cleaving protease (ADAMTS13) [6] . Impairment of ADAMTS13 activity, caused either by hereditary deficiency or by acquired autoantibodies that specifically inhibit ADAMTS13 function, leads to an excessive accumulation of ul-vWF that may lead to the onset of TTP [7, 8] . Most clinically observed cases of TTP in adults are acquired cases [1-3,9], with most patients having detectable levels of autoantibodies to ADAMTS13.
Patients with acquired idiopathic TTP frequently respond to plasma exchange therapy by the active removal of inhibitory antibodies and the restoration of functional ADAMTS13 activity from the infused donor plasma. A fraction of TTP patients, however, are either refractory to plasma exchange or are unable to achieve independence from plasma exchange or infusions. In these cases, immunosuppressive therapy directly targeting autoantibody inhibitors of ADAMTS13 could increase remission rates in patients with refractory disease and could enable patients to become independent of plasma-based therapies. Patients with inhibitors of ADAMTS13 and severely deficient functional activity appear to be predisposed to relapse after the tapering of plasma exchange. For example, Vesely et al. [9] showed an inverse relation between severe ADAMTS13 deficiency and TTP relapses or exacerbations of TTP. Among the patients with a severe deficiency, nearly all cases were secondary to an autoantibody inhibitor. Therefore, a persistent antibody inhibitor of ADAMTS13 likely is a key factor contributing to higher rates of exacerbation and relapse in patients with idiopathic TTP. Similarly, a recent prospective study by Zheng et al. [10 •• ] reported that three of four patients with a severe protease deficiency and high-titer inhibitory antibodies had a chronic relapsing course of their disease.
Studt et al. [11 •• ] also described identical twin sisters treated with plasma exchange for acute TTP. Both sisters had a severe deficiency of ADAMTS13 activity (<5%) and an antibody inhibitor of ADAMTS13 that persisted in both twins after remission was obtained and likely contributed to a relapse in one of the twins. Effective targeting of the antibody inhibitor of ADAMTS13 therefore also has the potential to prevent future relapses and the development of a chronic relapsing form of the disease. [29] [30] [31] [32] , cyclophosphamide, and intravenous immunoglobulin have also been reported to be successful in achieving clinical remission of refractory TTP. This review, however, focuses on recent reports studying corticosteroids, rituximab, and cyclosporine in the treatment of acquired TTP.
Corticosteroids
Corticosteroids are capable of modifying expression of multiple genes and are often used as an adjunct to plasma exchange therapy during initial therapy or are added later in cases of suboptimal or poor response to plasma exchange. Although there are multiple potential mechanisms of action of corticosteroids in TTP, the documented effectiveness in other antibody-mediated disorders including idiopathic thrombocytopenic purpura and hemolytic anemia have logically led to the use of steroids in acquired TTP. Despite their widespread use, no data yet clearly demonstrate the clinical efficacy of corticosteroids in the treatment of TTP or prevention of relapses. Due to the lack of randomized data and multiple confounding variables in the existing reports, the definitive role of corticosteroids in the treatment of TTP remains unclear. Ashida et al. [33] reported a case of TTP in a 9-month-old infant treated with a combination of plasma exchange and the addition of pulse methylprednisolone followed by a 2-month tapering course of prednisone. Prior to the initiation of therapy the child was shown to have a high titer of a neutralizing inhibitor of ADAMTS13 as well as less than 3% in-vitro ADAMTS13 activity. Beginning approximately 2 months from the initiation of the corticosteroids and more than a month after the last exchange procedure, there was a gradual decrement in the inhibitor titer as well as a progressive increase in ADAMTS13 activity that progressively improved even after all therapy (with the exception of rare infusions of fresh-frozen plasma) had been discontinued. The normalization of ADAMTS13 activity and undetectable inhibitor persisted roughly 26 months from the initiation of therapy and 24 months from the end of the corticosteroids. These results support an improvement in ADAMTS13 activity and inhibitor titers through the action of corticosteroids, although the data are confounded by the additional administration of intravenous immunoglobulin (480 mg/kg/d) for 4 days early in the course of therapy.
Contradictory data were presented by Zheng et al. [10 •• ], who prospectively studied ADAMTS13 activity and inhibitor titers in 37 patients, 20 of whom were categorized as having idiopathic TTP. Of the four patients reported with undetectable ADAMTS13 activity and high-titer inhibitors of the protease, two were treated with corticosteroids as an adjunct to plasma exchange. Both showed no sustained improvement in ADAMTS13 activity or inhibitor titers during the follow-up period. One patient only transiently decreased their inhibitor titer, with no improvement in ADAMTS13 activity, and the other patient had no initial improvement prior to undergoing a splenectomy that likewise had no effect on either surrogate marker. Explanations for the variable results of prednisone therapy likely arise from the heterogeneous nature of acquired TTP. Clearly, more prospective data from larger cohorts of patients studying ADAMTS13 and inhibitor titers are required to define the role of corticosteroids in the management of acquired TTP.
Rituximab
Rituximab, a monoclonal antibody that targets CD20 and depletes B cells, has been reported to be effective in patients with refractory TTP [14 •• ,15 • ,16-18,27 • , [34] [35] [36] . This novel application is based on the prediction that rituximab depletes the B-cell clone producing ADAMTS13 inhibitory antibodies, leading to a remission of the disease. Rituximab was shown to result in the temporary depletion of peripheral blood B cells lasting 3-12 months, after which B cells are typically replenished [37] . Because rituximab targets antibody-producing cells, the clinical response to rituximab would be expected to be delayed in acquired TTP. It is not yet clear, however, from the limited data available how B-cell regeneration after rituximab therapy will impact on the rate of relapse of the disease. . This patient also demonstrated suppression of the inhibitor and an increase in ADAMTS13 activity, but during long-term remission ADAMTS13 activity remained subnormal and inhibitors detectable. The significance and impact of these observations on the future risk of relapse remain to be determined.
Similarly, Reddy et al. [36] treated five patients with relapsed TTP with the addition of rituximab to plasma exchange and reported ADAMTS13 activity and inhibitor titers in addition to clinical response data. Four of the five patients with documented inhibitors and decreased ADAMTS13 activity prior to therapy had suppression of inhibitors and normalization of ADAMTS13 activity after treatment with rituximab. A summary of the recent case reports of patients treated with rituximab and plasma exchange reporting ADAMTS13 activity and inhibitor activity along with clinical data is presented in Table 1 . The case report and review of the literature from Yomtovian et al. suggest that patients may be susceptible to relapse after a certain period from inhibitory antibodies that persist at a low level or following the regeneration of B cells after rituximab has been discontinued. Clearly, more data detailing the relation of ADAMTS13 and inhibitory antibody activity to clinical relapses of TTP throughout follow-up are needed to evaluate the long-term effectiveness of any therapy targeting antibody inhibitors of ADAMTS13.
From the data presented it is fairly clear that rituximab is potentially very useful in the treatment of refractory TTP as well as in the chronic relapsing form of the disease. Despite its effectiveness in TTP, practical issues remain including the active removal of rituximab by plasma exchange if given concurrent with plasma exchange. Immune-based treatment targeting ADAMTS13 inhibitory antibodies would ideally be started at the time of diagnosis at the same time plasma-based therapies are initiated to allow for more rapid tapering and decreased dependence on plasma exchange or infusions. Further studies are needed to determine the best strategy by which rituximab can be best incorporated into the main therapeutic regimen of plasma exchange during acute TTP. In addition, although rituximab is typically well tolerated, it has been associated with significant infusion, hematologic, and pulmonary toxicities that have occasionally been fatal. These questions must be addressed going forward to determine the most appropriate dose and schedule of rituximab administration to achieve the desired suppression of antibody inhibitors of ADAMTS13. 
Cyclosporine
Cyclosporine complexes with cyclophilin to inhibit the phosphatase activity of calcineurin. By preventing calcineurinmediated dephosphorylation, cyclosporine inhibits helper T-cell functions that are necessary to induce B-cell differentiation and generate an effective antibody response. Kierdorf et al. [25] reported what is likely the first use of cyclosporine to treat TTP resistant to plasma exchange. Plasma exchange therapy was discontinued and cyclosporine started at a dose of 300 mg/d with a complete remission of the disease occurring after 8 days. The patient discontinued the cyclosporine after 3 months and 3 months later had a relapse that was effectively treated with cyclosporine alone, with a complete remission occurring after 10 days. Since then there have been several reports of the effectiveness of cyclosporine as an adjunct to plasma exchange, enabling patients with relapsing/refractory TTP to achieve remission and independence from plasma-based therapy (Table 2 ) [19, [21] [22] [23] [24] [25] [26] . Most studies, however, did not measure the effect of cyclosporine on ADAMTS13 level and inhibitor activity, with the exception of a recent case report by Nosari et al. [23] suggesting that cyclosporine resulted in a remission of TTP and a normalization of ADAMTS13 activity in one patient known to have an antibody inhibitor of the protease. Although these reports suggest the efficacy of cyclosporine in resistant cases of TTP, prospective study of cyclosporine in the context of systematically timed measurements of ADAMTS13 and inhibitor status is needed to judge the efficacy of cyclosporine and to define the precise mechanism of action of cyclosporine in idiopathic TTP.
As with rituximab, initial reports suggest that despite its effectiveness, patients are susceptible to relapse after the cyclosporine is tapered. In the reports by Kierdorf et al. [25] and Hand et al. [20] , despite several months of cyclosporine treatment (3 and 12 months, respectively), both patients had relapses approximately 6 and 2 months, respectively, after discontinuing therapy but successfully achieved remission after restarting cyclosporine without plasma exchange or infusions. These preliminary data argue for longer-term administration of cyclosporine to maintain remissions of TTP. Prospective data detailing the effects of cyclosporine on both ADAMTS13 activity and inhibitor titers studied in the context of clinical data throughout long-term follow-up are needed before any informed decisions or recommendations can be made.
Conclusion
Despite the effectiveness of rituximab and cyclosporine in achieving clinical remission of refractory TTP, several patients relapsed after tapering cyclosporine, or in the case of rituximab, relapsed several months after the last infusion of the antibody. Given the potential for devastating complications from each acute episode of TTP, an effective maintenance therapy targeting the inhibitor of ADAMTS13 to improve protease function is a logical step to prevent further relapses of TTP. Before these questions can be answered, however, better prospective data defining the relation of ADAMTS13 activity and antibody inhibitors to the risk of relapse are required. This will be the best means of determining whether a particular therapy prevented or minimized the risk of future events in a patient destined to relapse. It will also prevent patients at a low risk of relapse of TTP from being exposed to potential toxicity from the long-term administration of an immunosuppressive therapy. If immunosuppressive therapy can effectively suppress inhibitors of ADAMTS13, an obvious advantage would be to start therapy concurrent with plasma exchange to enable more rapid tapering of plasma exchange, thus minimizing exposure to donor plasma and other complications of the procedure. Cyclosporine concentrations have been reported not to be significantly affected by when given concurrent with plasma exchange, but no data exist on the effect of plasma exchange on plasma levels or efficacy of rituximab therapy in TTP [38] . These questions, among others, will need to be addressed going forward as immune-based therapies are increasingly applied to the treatment of acute and relapsed/refractory TTP.
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